A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma

Trial Profile

A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2016 Status changed from active, no longer recruiting to discontinued as it was administratively complete.
    • 07 May 2013 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 May 2013 Planned number of patients changed from 50 to 25 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top